Lifevantage 2026 Q1 Earnings Strong Performance with 18% Net Income Growth

Lifevantage (LFVN) reported mixed results for Q1 2026, with revenue slightly above the prior year but below analyst estimates. Earnings per share (EPS) and net income both showed robust growth, driven by cost efficiencies and strategic initiatives.

Revenue

, , . , , respectively. The company maintained stable revenue despite seasonal challenges and integration costs from the LoveBiome acquisition.

Earnings/Net Income

, . The earnings growth outperformed revenue, signaling improved profitability through operational efficiencies.

Price Action

, , , reflecting investor concerns over margin pressures and integration risks.

Post-Earnings Price Action Review

Despite stable revenue, the stock’s decline highlighted market skepticism about long-term growth. A backtest of buying shares after quarterly revenue drops showed no data for analysis due to three years of consistent revenue. The acquisition of LoveBiome and strategic product launches remain key focus areas.

CEO Commentary

CEO emphasized the LoveBiome integration as a transformative move, positioning Lifevantage in the gut health market. He highlighted the HealthyEdge product stack and robust consultant training programs as drivers for future growth.

Guidance

. Second-half performance is expected to outpace the first half due to seasonality and LoveBiome synergies.

Additional News

Lifevantage completed the LoveBiome acquisition, expanding its microbiome product portfolio and consultant base. , payable on December 15, 2025, reflecting confidence in its cash position. Recent M&A activity and dividend increases underscore its focus on shareholder returns and market expansion.